Preliminary program

Home » Preliminary program

HYPERTROPHIC CARDIOMYOPATHY

  • Genetic basis of HCM
  • New Frontiers: Gene therapy in HCM
  • Myosin Inhibitors: Are they the philosophers’ stone for HCM?
  • Controversies in HOCM treatment
    • Is there a new role for betablockers?
    • Is there any role for myectomy?
    • Is septal alcohol ablation safe and effective?
  • Controversies in HCM risk stratification
    • Must we include genetics in SCD HCM risk-score?
    • Role of MRI LGE and apical aneurism in risk stratification
    • Role of blood pressure response
    • Risk stratification in pediatric population
    • Sports in HCM patients

 

CARDIAC TTR AMYLOIDOSIS  (ATTR-CM)

  • New treatments in cardiac ATTR
  • Are DPD scintigraphy or cardiac MRI 100% specific for the diagnosis?
  • When to start treatment in TTR carriers?

 

FABRY DISEASE

  • When to start treatment in women?
  • Role of cardiac MRI in the diagnosis
  • Is LysoGB3 the solution for the diagnosis and the follow up?